Analyst Ratings for [JNCE] Jounce Therapeutics, Inc.

JNCE Jounce Therapeutics, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. The Company’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates Inducible T cell CO-Stimulator (ICOS) and is in a Phase II trial.

5/11/22	Downgrades	Outperform Neutral	X
JNCE Jounce Therapeutics Robert W. Baird
$15 $7
5/6/22	Upgrades	Outperform Strong Buy	X
JNCE Jounce Therapeutics Raymond James
$15 $20
3/16/22	Initiated	Outperform	X
JNCE Jounce Therapeutics SMBC Nikko
$17
2/4/22	Upgrades	Mkt Perform Outperform	X
JNCE Jounce Therapeutics Cowen
3/15/21	Initiated	Overweight	X
JNCE Jounce Therapeutics Piper Sandler
$20
11/14/18	Downgrades	Neutral Underweight	X
JNCE Jounce Therapeutics JP Morgan
6/28/18	Initiated	Outperform	X
JNCE Jounce Therapeutics Raymond James
5/17/18	Downgrades	Outperform Mkt Perform	X
JNCE Jounce Therapeutics Wells Fargo
4/27/18	Initiated	Buy	X
JNCE Jounce Therapeutics H.C. Wainwright
$33